Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Isolation of human pluripotent stem-cell derived left ventricular cardiomyocytes for use in myocardial infarction treatment

EF 2019-20

Résumé
"Myocardial infarctions, more commonly known as heart attacks, are ailments that can afflict a vast majority of a population through a variety of means. Normally, this cardiovascular disease occurs when a blot clot, or some other blockage, forms and prevents blood flow within a vessel in the heart. The lack of blood flow causes the heart muscle cells to stop receiving oxygen and, in a short amount of time, die. The causes of myocardial infarctions are quite well known, with cholesterol build up in arteries being chief among them. However, current treatments for myocardial infarction primarily tackle trying to remove the blockage that is preventing blood flow. As such, there are limited options for treating the muscle cell death that also occurs. Recent advances in human pluripotent stem cell (hPSC) technology have shown promise in being able to regenerate dead cell tissue for this purpose. A sample of connective tissue can be taken from a patient and treated with various factors to form a particular subtype of cell, via hPSCs. While this technique has been previously applied in treating myocardial infarction, it has been faced with limited results due to an inability to produce the specific cardiac muscle cell types needed for treatment. This project aims to use newly identified factors to develop a robust hPSC differentiation protocol for left ventricular cardiac muscle cells, the common dead cell type following myocardial infarction. Additionally, this project aims to use these cells to develop a better tissue-culture model of myocardial infarction in order to create a novel treatment modality. It is the aim that by using specified hPSC technology we can more directly treat myocardial infarctions and improve physiological outcomes."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428864
Name
Iyengar Yajur
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Isolation of human pluripotent stem-cell derived left ventricular cardiomyocytes for use in myocardial infarction treatment
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiomyocytes; Cell-Based Therapy; Differentiation Protocols; Fluorescence Activated Cell Sorting; Human Induced Pluripotent Stem Cells; Isolated Perfused Heart Model; Myocardial Infarction; Ventricular Mesoderm
Abstract
"Myocardial infarctions, more commonly known as heart attacks, are ailments that can afflict a vast majority of a population through a variety of means. Normally, this cardiovascular disease occurs when a blot clot, or some other blockage, forms and prevents blood flow within a vessel in the heart. The lack of blood flow causes the heart muscle cells to stop receiving oxygen and, in a short amount of time, die. The causes of myocardial infarctions are quite well known, with cholesterol build up in arteries being chief among them. However, current treatments for myocardial infarction primarily tackle trying to remove the blockage that is preventing blood flow. As such, there are limited options for treating the muscle cell death that also occurs. Recent advances in human pluripotent stem cell (hPSC) technology have shown promise in being able to regenerate dead cell tissue for this purpose. A sample of connective tissue can be taken from a patient and treated with various factors to form a particular subtype of cell, via hPSCs. While this technique has been previously applied in treating myocardial infarction, it has been faced with limited results due to an inability to produce the specific cardiac muscle cell types needed for treatment. This project aims to use newly identified factors to develop a robust hPSC differentiation protocol for left ventricular cardiac muscle cells, the common dead cell type following myocardial infarction. Additionally, this project aims to use these cells to develop a better tissue-culture model of myocardial infarction in order to create a novel treatment modality. It is the aim that by using specified hPSC technology we can more directly treat myocardial infarctions and improve physiological outcomes."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Iyengar, Yajur
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~